MKI67 and hepatocellular carcinoma: The validation cohort was divided into group 1 (HCC tumors with Ki-67 index above 17.5%, n=20, and the number of FDG-avid lesions was 14, the number of non-FDG-avid lesions was 6) and group 2 (HCC tumors with Ki-67 index below 17.5%, n=10, and the number of FDG-avid lesions was 0, the number of non-FDG-avid lesions was 10).